New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 15, 2014
11:01 EDTDANG, FOSL, MDVN, NUAN, GOGOOptions with decreasing implied volatility: GOGO MDVN FOSL NUAN DANG
News For GOGO;MDVN;FOSL;NUAN;DANG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 2, 2015
11:07 EDTFOSLVera Bradley surges on better-than-expected Q2 earnings, upbeat FY16 view
Shares of Vera Bradley (VRA) surged in morning trading after the company reported better-than-expected second quarter results and raised its outlook for fiscal year 2016. Vera Bradley is a designer of women's handbags, accessories, luggage and travel items and eyewear. WHAT'S NEW: Vera Bradley reported Q2 earnings per share from continuing operations of 15c on revenue of $120.7M, beating analysts' expectations of 11c and $114.99M, respectively. Same-store sales decreased 15% for the quarter, though Robert Wallstrom, the company's chief executive officer, said that the company's comparable sales trend began to improve toward the end of the quarter due to new product offerings, improved in-store execution and initial marketing efforts. Looking ahead, Vera Bradley forecast third quarter EPS from continuing operations of 19c-21c on revenue of $120M-$123M, against analysts' consensus estimates of 15c and $117.2M, respectively. Wallstrom said that the company's turnaround will take time, but noted "meaningful progress" being made, and that Vera Bradley is "confident" in its long-term strategic plan. WHAT'S NOTABLE: Vera Bradley raised its FY16 continuing operations EPS view to 72c-82c from 64c-74c, higher than analysts' expectations of 66c. Additionally, the company's FY16 revenue view was narrowed to $487M-$495M from $480M-$495M, still ahead of analysts' consensus estimates of $481.57M. On its Q2 earnings conference call, Vera Bradley forecast sees Q3 and FY16 same-store sales down in the low double-digit percentage range. The company added that it eliminated hyperpromotions and pared back promotional days in Q2 and noted that it is seeing "green shoots" from its turnaround efforts. Vera Bradley said it sees a decline in hyperpromotional activity in FY16. PRICE ACTION: Vera Bradley shares are up 23.49% to $12.88 in morning trading. OTHERS TO WATCH: Vera Bradley peers include Coach (COH), down 0.54%, Michael Kors (KORS), up 1.92%, and Fossil Group (FOSL), up 0.64%.
10:16 EDTDANGOptions with decreasing implied volatility
Subscribe for More Information
September 1, 2015
09:25 EDTDANGOn The Fly: Pre-market Movers
Subscribe for More Information
05:13 EDTDANGDangdang reports Q2 EPS (RMB 0.26) vs. RMB 0.36 last year
Subscribe for More Information
August 28, 2015
07:12 EDTMDVNWilliam Blair names 21 stocks best positioned for volatile markets
Subscribe for More Information
August 27, 2015
15:18 EDTFOSLMovado spikes after reporting Q2 results, backing FY16 guidance
Movado Group (MOV), which designs, sources, markets and distributes watches, is trading sharply higher after reporting better than expected second quarter earnings and revenue, as well as backing its fiscal 2016 guidance. WHAT'S NEW: Movado reported Q2 earnings per share of 50c against a consensus of 42c, and Q2 revenue of $145.6M against a consensus of $142.25M. The company also backed its FY16 EPS view of $2.00-$2.10 against a consensus of $2.05, and backed its FY16 revenue view of $590M-$600M against a consensus of $593.13M. Movado said it anticipates recording the remainder of the previously announced $3M-$4M pre-tax charge related to operating efficiency initiatives by the end of FY16, which is excluded from its guidance. ANALYST RESEARCH: On August 25, Barrington Research released an earnings preview that advised staying "on the sidelines" with Movado, forecasting the company's EPS at 40c and its revenue at $144.3M. The firm, which had rated Movado at Market Perform, correctly predicted the company would maintain its guidance. PRICE ACTION: In late afternoon trading, Movado is higher by $3.93, or 17.6%, to $26.25. PEERS: Competitor Fossil Group (FOSL) is trading higher by 2.6%.
08:35 EDTMDVNMedivation price target raised to $166 at William Blair after talazoparib deal
Subscribe for More Information
August 24, 2015
18:55 EDTNUANOn The Fly: After Hours Movers
Subscribe for More Information
10:49 EDTGOGOGogo announces receipt of final clearance from FAA to launch 2Ku service
Subscribe for More Information
09:49 EDTFOSLFitbit being sold at Macy's seen as near-term catalyst
Subscribe for More Information
07:02 EDTMDVNMedivation to acquire worldwide rights to Talazoparib from BioMarin
Medivation (MDVN) and BioMarin Pharmaceutical (BMRN) have entered into an asset purchase agreement under which Medivation will acquire all worldwide rights to talazoparib, a highly-potent, orally-available poly ADP ribose polymerase inhibitor currently in a Phase 3 study for the treatment of patients with deleterious germline BRCA 1 or BRCA 2 mutations and locally advanced and/or metastatic breast cancer. Under the agreement, Medivation will be responsible for all research, development, regulatory and commercialization activities for all indications on a global basis. Under the terms of the agreement, Medivation will pay BioMarin $410 million upfront, up to an additional $160 million upon the achievement of regulatory and sales-based milestones and mid-single digit royalties for talazoparib. At the closing of the transaction, Medivation will assume all financial obligations associated with the development and commercialization of talazoparib. The closing of the transaction is conditioned on the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. The transaction is anticipated to close in 2015.
August 20, 2015
10:00 EDTFOSLOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
06:55 EDTFOSLFossil upgraded to Sector Weight from Underweight at KeyBanc
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use